Premium
Argatroban use during pediatric interventional cardiac catheterization
Author(s) -
Cetta Frank,
Graham Lynn C.,
Wrona Laura L.,
Arruda M. Janine,
Walenga Jeanine M.
Publication year - 2004
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10720
Subject(s) - argatroban , medicine , activated clotting time , bolus (digestion) , heparin , heparin induced thrombocytopenia , catheter , thrombosis , direct thrombin inhibitor , bivalirudin , surgery , anesthesia , percutaneous coronary intervention , warfarin , dabigatran , thrombin , platelet , atrial fibrillation , myocardial infarction
Argatroban is a synthetic direct thrombin inhibitor that does not interact with or induce heparin‐dependent antibodies. It is approved for use in adults for prevention and treatment of thrombosis associated with heparin‐induced thrombocytopenia (HIT). It has been administered safely in adults with HIT during coronary interventions. There are no reports of argatroban use for anticoagulation in pediatric patients. The present case describes the use of argatroban during coil embolization of a Fontan fenestration in a child with a history of HIT. The patient received a single bolus dose of 150 μg/kg of argatroban at the onset of the intervention. The fenestration was successfully occluded with a detachable coil. The activated clotting time (ACT) was > 200 sec throughout the procedure. The ACT returned to baseline 72 min after the bolus. No complications occurred. This case demonstrates the safe and successful use of argatroban during a transcatheter intervention in a pediatric patient with a history of HIT. The use of argatroban is promising for anticoagulation in children who require an alternative to heparin. Catheter Cardiovasc Interv 2004;61:147–149. © 2004 Wiley‐Liss, Inc.